



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

February 7, 2024

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclosed herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	<p>1) Name of the target entity Eywa Pharma Pte Ltd</p> <p>2) Details in brief such as size, turnover etc. Eywa Pharma Pte Ltd is incorporated out of Singapore. For the year ended December 31, 2023, the consolidated gross revenue is US\$ 19.16 million.</p>
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
C	Industry to which the entity being acquired belongs	Pharmaceuticals
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Company is engaged in the business of pharmaceuticals. Investment of US\$ 3 million originally made on January 13, 2023 for 2.80% shareholding on a fully diluted basis. Now the shares are allotted on account of anti-dilution rights making the shareholding to 7.07% on a fully diluted basis.
E	Brief details of any governmental or regulatory approvals required for the acquisition	Under Foreign Exchange Management (Overseas Investment) Rules, 2022 and subject to applicable regulatory approvals, if any
F	Indicative time period for completion of the acquisition;	Not applicable
G	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration of US\$ 3 million earlier invested on January 13, 2023
H	Cost of acquisition or the price at which the shares are acquired	7.07% shareholding (Increase is on account of anti-dilution shares receivable to protect the investment value of approximately US\$ 3 million already made)
I	Percentage of shareholding / control acquired and / or number of shares acquired	7.07% shareholding



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Sl. No.	Particulars	Details of Investment
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>1. Brief background:</p> <p>Eywa Pharma Pte Ltd sells pharmaceutical formulations.</p> <p>2. Line of business:</p> <p>Pharmaceuticals</p> <p>3. Date of incorporation:</p> <p>May 13, 2015</p> <p>4. Turnover of last 3 years ending December 31 (in US\$ million):</p> <p>For the year 2023: 19.16 For the year 2022: 27.01 For the year 2021: 25.05</p> <p>5. Country in which the acquired entity has presence:</p> <p>Singapore</p>